Shanshan Pei, PhD
I am fascinated by the potential of precision medicine in cancer, particularly for leukemia. Decades of work in the field have extended our understanding of leukemia biology with regard to genetics, epigenetics, and metabolism, and we now have many pieces
to the puzzle. Our ability to uncover more pieces is further enabled by a recent outburst of powerful omics techniques and data analysis tools. Thus, we now have a unique opportunity to comprehensively dissect both intra- and inter- AML patient heterogeneity.
We can then connect these data to their individual therapeutic response in the clinic. This intersection of research, clinic, and data science is an exciting space for precision drug discovery in AML.
In this context, I am particularly
interested in utilizing multi-omic approaches at both population and single-cell levels to pinpoint key biological differences between therapy responders and non-responders in current clinical trials. I am also interested in using drug/genetic screens
in ex vivo and in vivo settings to identify novel therapies that can target mechanisms of resistance in non-responders. Finally, in line with my overall fascination of precision medicine, I am interested in working with physicians, bench
scientists and data scientists to build databases and analysis pipelines for implementing data-driven precision medicine in the near future.